Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × tucatinib × 90 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Colorectal Neoplasms 4 Neoplasms 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Multiple Myeloma 2 Lymphoma, Non-Hodgkin 2 Rectal Neoplasms 1 Pathologic Complete Response 1 Neoplasm Metastasis 1 Meningeal Neoplasms 1 Hemangiosarcoma 1 HER2-positive Metastatic Breast Cancer 1 HER2-positive Breast Cancer 1 Gallbladder Neoplasms 1 Esophageal Neoplasms 1 Colonic Neoplasms 1 Cholangiocarcinoma 1 Brain Neoplasms 1 Adenocarcinoma Of Esophagus 1 Adenocarcinoma 1

Interventions

pertuzumab 2 Trastuzumab 2 tucatinib 1 pyrotinib 1 Paclitaxel 1 Fluorodeoxyglucose F18 1 Docetaxel 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07413939 2026-03-10

BREnnA

Hoffmann-La Roche

Phase 2/3 Not yet recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡